Experts and Doctors on tumor suppressor protein p53 in Oxford, England, United Kingdom

Summary

Locale: Oxford, England, United Kingdom
Topic: tumor suppressor protein p53

Top Publications

  1. Robinson R, Lu X, Jones E, Siebold C. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure. 2008;16:259-68 pubmed publisher
    ..These results suggest that the binding properties of iASPP render it a target for antitumor therapeutics and provide a peptide-based template for compound design. ..
  2. Murray Zmijewski F, Slee E, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol. 2008;9:702-12 pubmed publisher
    ..The precise combination of these marks, much like the bars in a barcode, dictates the behaviour of p53 in any given situation. ..
  3. Lu X. Tied up in loops: positive and negative autoregulation of p53. Cold Spring Harb Perspect Biol. 2010;2:a000984 pubmed publisher
    ..Such knowledge may ultimately lead to the development of more effective anticancer therapeutics. ..
  4. Adams C, Pike A, Maniam S, Sharpe T, Coutts A, Knapp S, et al. The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structure. Proc Natl Acad Sci U S A. 2012;109:3778-83 pubmed publisher
    ..We show that both of the TPR and OB-fold domains localize to the chromatin of p53 target genes and exhibit intrinsic regulatory activity necessary for the Strap-dependent p53 response. ..
  5. Azad A, Fox J, Leverrier S, Storey A. Blockade of the BAK hydrophobic groove by inhibitory phosphorylation regulates commitment to apoptosis. PLoS ONE. 2012;7:e49601 pubmed publisher
    ..Our study reveals important novel mechanistic and structural insights into the temporal sequence of events governing the process of BAK activation in commitment to cell death and how they are regulated. ..
  6. Andreeff M, Kelly K, Yee K, Assouline S, Strair R, Popplewell L, et al. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2016;22:868-76 pubmed publisher
    ..MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies. ..